Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 11Prostatic Neoplasms 10Breast Neoplasms 8Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lung Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Thrombocythemia, Essential 2Testicular Neoplasms 2Stomach Neoplasms 2Skin Diseases 2Primary Myelofibrosis 2Polycythemia Vera 2Myeloproliferative Disorders 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Hodgkin Disease 2Hematologic Diseases 2Glioma 2Burkitt Lymphoma 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Uveal Melanoma 1

Interventions

lutetium Lu 177 dotatate 1copper dotatate CU-64 1Watchful Waiting 1Patient Reported Outcome Measures 1Mitomycin 1Lutetium-177 1Lutetium 1Drug Therapy 1Colonoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Neoplasms by Site × Watchful Waiting × Clear all
NCT04016935 2022-05-17

EndoPredict® Extended Endocrine Trial (EXET)

Myriad Genetic Laboratories, Inc.

Terminated
855 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡